RECRUITING

The Epidemiology and Pathophysiology of Kidney Disease in HFpEF With Obesity

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This research study wants to learn about Chronic Kidney Disease (CKD) with Obesity, and Heart Failure with preserved Ejection Fraction (HFpEF) and better ways to evaluate these diseases. HFpEF means that the heart is not able to fill properly with blood while it is resting so the amount of blood pumped out to the body is less than it would be if it was filling properly. The study is being done to describe the differences in how the kidneys handle protein and salt in participants with HFpEF and obesity compared to healthy persons.

Official Title

The Epidemiology and Pathophysiology of Kidney Disease in HFpEF With Obesity

Quick Facts

Study Start:2022-07-22
Study Completion:2026-07-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT07052539

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 75 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Adults 18-75 years old
  2. * Normal kidney function
  3. * No heart failure
  4. * BMI 25-30kg/m2
  1. * Diagnosis of chronic illness
  2. * eGFR\<60mL/min/1.73m2
  3. * Pregnancy or breast feeding
  4. * History of cutaneous or allergic reaction to iodine-based products of contrast dyes
  5. * Hemoglobin levels \<7mg/dL
  6. * Acute illness or hospitalization event within 3 months
  7. * Unable to stop NSAIDs
  8. * Comorbid conditions: MM, amyloidosis, pheochromocytoma, SCD, metastatic brain lesions, advanced kidney disease, liver dysfunction, endotoxemia, hyperthyroidism
  9. * Current use of nicotine or recreational drugs, chronic drinker

Contacts and Locations

Study Contact

Tekka Johnson
CONTACT
601-496-7834
tjohnson23@umc.edu

Principal Investigator

Marissa C Tio, MD
PRINCIPAL_INVESTIGATOR
University of Mississippi Medical Center

Study Locations (Sites)

University of Mississippi Medical Center
Jackson, Mississippi, 39216
United States

Collaborators and Investigators

Sponsor: University of Mississippi Medical Center

  • Marissa C Tio, MD, PRINCIPAL_INVESTIGATOR, University of Mississippi Medical Center

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2022-07-22
Study Completion Date2026-07-31

Study Record Updates

Study Start Date2022-07-22
Study Completion Date2026-07-31

Terms related to this study

Additional Relevant MeSH Terms

  • Chronic Kidney Disease
  • Heart Failure With Preserved Ejection Fraction (HFPEF)
  • Obesity (Disorder)